Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.Ask about treatment

Breast cancer: US-approved treatments and how families in the Gulf can access them

Name: Breast cancer: US-approved treatments and Gulf access | Reserve Meds
Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Breast cancer: the short answer

The US FDA has approved nine medicines covered on this page for breast cancer, each for a specific group of patients: Enhertu, Datroway, Trodelvy, Kisqali, Verzenio, Itovebi, Truqap, Inluriyo and Lynparza. On 17 October 2026, nine of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Enhertu, Datroway, Trodelvy, Kisqali, Verzenio, Itovebi, Truqap, Inluriyo and Lynparza.
Gulf registers (checked 17 October 2026): see each medicine below.
Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is breast cancer?

Breast cancer is treated with a plan that often uses more than one type of treatment. Local treatments, such as surgery (lumpectomy or mastectomy) and radiation, treat the area with cancer. Systemic treatments, such as chemotherapy, hormone therapy, targeted therapy and immunotherapy, reach cancer cells throughout the body.^[1]

There are different treatment approaches for each type and stage of breast cancer. The US labels below are written for specific types: HER2-positive, HER2-low, hormone receptor (HR)-positive and HER2-negative, and triple-negative breast cancer, and some also require a gene change such as PIK3CA, AKT1, PTEN, ESR1 or an inherited BRCA mutation.^{[1, 2, 3, 4, 5]}

Hormone therapy helps lower the risk of recurrence of certain types of breast cancer, and immunotherapy may be used to treat triple-negative breast cancer.^[1]

Breast cancer in the Gulf

Breast cancer epidemiology in the Gulf has been compared with international data (Clinical Breast Cancer, 2018), and a 2022 population-based cohort study in The Lancet Oncology examined genetic predisposition to cancer across people of different ancestries in Qatar.^{[6, 7]}

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 8 of 9 were listed in Saudi Arabia and 8 of 9 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.^{[8, 9]}

US FDA-approved medicines for breast cancer

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Enhertu (fam-trastuzumab deruxtecan-nxki)
US FDA-approved for HER2-positive breast cancer in early and advanced stages, and HER2-low or HER2-ultralow metastatic breast cancer, as set out in its label. It is an antibody-drug conjugate infusion.^[2]
Current US label version: 15 May 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Datroway (datopotamab deruxtecan-dlnk)
US FDA-approved for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and chemotherapy, and triple-negative breast cancer in patients who cannot have PD-1 or PD-L1 immunotherapy. It is an antibody-drug conjugate infusion.^[10]
Current US label version: 27 May 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Kuwait, Egypt, Iraq, Turkey
Trodelvy (sacituzumab govitecan-hziy)
US FDA-approved for unresectable locally advanced or metastatic triple-negative breast cancer, including first-line use when PD-1 or PD-L1 immunotherapy is not suitable, and some HR-positive, HER2-negative metastatic breast cancer. It is an infusion.^[11]
Current US label version: 24 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Kisqali (ribociclib)
US FDA-approved for HR-positive, HER2-negative breast cancer: adjuvant treatment of high-risk stage II and III early breast cancer with an aromatase inhibitor, and advanced or metastatic disease. It is a tablet.^[12]
Current US label version: 1 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Egypt
Verzenio (abemaciclib)
US FDA-approved for HR-positive, HER2-negative breast cancer: adjuvant treatment of node-positive, high-risk early breast cancer with endocrine therapy, and advanced or metastatic disease. It is a tablet.^[13]
Current US label version: 18 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan
Itovebi (inavolisib)
US FDA-approved for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, with palbociclib and fulvestrant. It is a tablet.^[14]
Current US label version: 21 April 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Bahrain, Egypt, Lebanon, Turkey
Truqap (capivasertib)
US FDA-approved for adults with HR-positive, HER2-negative advanced breast cancer with one or more PIK3CA, AKT1 or PTEN changes, with fulvestrant. It is a tablet.^[3]
Current US label version: 16 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Qatar, Bahrain, Oman, Egypt
Inluriyo (imlunestrant)
US FDA-approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after at least one line of endocrine therapy. It is a tablet.^[4]
Current US label version: 18 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Qatar, Oman, Turkey
Lynparza (olaparib)
US FDA-approved for HER2-negative breast cancer in patients with an inherited BRCA mutation, including high-risk early breast cancer after chemotherapy and metastatic disease. It is a tablet.^[5]
Current US label version: 10 July 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[8, 9]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.^{[15, 16]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for breast cancer

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for breast cancer?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Enhertu, Datroway, Trodelvy, Kisqali, Verzenio, Itovebi, Truqap, Inluriyo and Lynparza. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Enhertu available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Enhertu?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Why do HER2 and hormone receptor results matter so much?

Most breast cancer medicines are approved only for specific tumor types, such as HER2-positive, HER2-low, HR-positive or triple-negative. The pathology report decides which US labels apply.

Sources for the condition-specific answers: ^{[2, 12, 11]}

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.